Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Bully88on Nov 23, 2020 11:06am
159 Views
Post# 31952197

RE:RE:RE:RE:Thank god Tripp didnt make any additional claims

RE:RE:RE:RE:Thank god Tripp didnt make any additional claims Honestly, 

I truly think it is just a case of too high of expectations and not enough information provided by SZLS

We have known from the beginning that they are pretty tight lipped when it comes to details and like to space them out and let us sweat lol

What we know is they put out a very detailed prospectus back in june.

They have been following that very diligently, and I definitely think that its a snowball effect when it comes to ramping up test numbers.

Q2 we started and were at 50 tests a day average based on income. Q3 we equate to being around a 250 - 300 tests per day average based on income. 

Whos to say they dont go 5x on tests done again in q4  with 50 new partnerships?! and hit 1250 - 1500 tests a day average?

maybe they didnt want to sign these 50 new contracts including what i feel is extremely under valued in signing with barbados and hawai before they had the lab up and ready and able to hit high gear.

Thats what i would do if i was them. I wouldnt want to look like a fool saying i can do 1000 tests a day for you, and you and you, over book and then have a backlog and look like chumps 



this could hit 3000 test this Q easily and we would easily see excess of 5 mil revenue no problem.

The thing is no one knows. 

But its happening.

They are growing their bank exponentially and growing their partnerships.

thats the most important aspect to take from all of this.

They are growing into a credible player and big companies dont want to partner with chumps

Aristotle is going to change so many lives here on this board.

Dont sweat the minor details and look at the big picture.

This technology is going to be a game changer and we are all in at a market cap of under 50 mil

mark my words.

Billion dollar evaluation one day




Liked2Think wrote: He knows if revenue for Q4 isnt way above 1.5M it will look bad.  All the talk of 1000 tests a day, ramping up, having to buy more supplies and hire more people so far has not equated to any additional revenue nor that it really should as it was all being done during Q3. Q4 results they will not be able to use the excuses of the past.  They have the people, they have the facility (even before the addition of more space) to do 1000 tests a day.

The only thing that can prevent that is the demand not being there.  Which sounds crazy but what other excuse could there be. 3000 tests per day is a pipe dream.  All I want is the 1000 we were promised/told we had capacity for months ago.  They have never said how many tests they are doing which worries me.  I believe if they gave us that number it would hurt the stock price.  Forget telling us how much we made the first 6 weeks of Q4.  Tell us how many tests have been completed in Oct.  Give us something.

Little worried about aristotle now "early 2021".  So technically it could be June 1 and still be considered "early 2021"?  Where is the cuttoff date for "early 2021".  We have no idea what the demand for covid testing will be if/when the vacine saves us all.  Will they need to continue testing, wont they?.  Testing will decline massively thats for sure.  If aristotle isnt up and running before then the stock price will suffer big time.  People will come for covid but why would they stay for cancer if its not ready.

Yes I am debbie downer today even with the stock currently in the green.  Bunch of good things out there but still more questions than answers and still we are left waiting for Q4 now.  


<< Previous
Bullboard Posts
Next >>